S100A13, a new marker of angiogenesis in human astrocytic gliomas

J Neurooncol. 2006 Dec;80(3):251-9. doi: 10.1007/s11060-006-9189-y. Epub 2006 Jun 14.

Abstract

S100 proteins are Ca(2+)-binding polypeptides involved in the tumourigenesis of several human neoplasms. S100A13 is a key regulator of the stress-dependent release of FGF1, the prototype of the FGF protein family involved in angiogenesis. Indeed, S100A13 is a copper binding protein able to enhance the export of FGF1 in response to stress in vitro and to induce the formation of a multiprotein aggregate responsible for FGF1 release. We investigated the expression of S100A13 in human astrocytic gliomas in relation to tumour grading and vascularization. A series of 26 astrocytic gliomas was studied to evaluate microvessel density and to assess FGF1, S100A13 and VEGF-A expression. FGF1 was equally expressed in the vast majority of tumours, whereas S100A13 and VEGF-A were significantly up-regulated in high-grade vascularized gliomas. Moreover, both S100A13 and VEGF-A expression significantly correlated with microvessel density and tumour grading. These data suggest that the up-regulation of S100A13 and VEGF-A expression correlates with the activation of angiogenesis in high-grade human astrocytic gliomas.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Astrocytoma / blood supply*
  • Astrocytoma / metabolism
  • Biomarkers, Tumor / metabolism*
  • Brain Neoplasms / blood supply*
  • Brain Neoplasms / metabolism
  • Female
  • Fibroblast Growth Factors / metabolism
  • Humans
  • Male
  • Middle Aged
  • Neovascularization, Pathologic / metabolism*
  • S100 Proteins / metabolism*
  • Severity of Illness Index
  • Statistics, Nonparametric
  • Up-Regulation
  • Vascular Endothelial Growth Factor A / metabolism*

Substances

  • Biomarkers, Tumor
  • S100 Proteins
  • S100A13 protein, human
  • Vascular Endothelial Growth Factor A
  • Fibroblast Growth Factors